L-StepholidineD2/D1 receptor agonist CAS# 16562-13-3 |
- Dexpramipexole dihydrochloride
Catalog No.:BCC1528
CAS No.:104632-27-1
- Dexpramipexole
Catalog No.:BCC1527
CAS No.:104632-28-2
- Cariprazine hydrochloride
Catalog No.:BCC1454
CAS No.:1083076-69-0
- Cariprazine
Catalog No.:BCC1453
CAS No.:839712-12-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 16562-13-3 | SDF | Download SDF |
| PubChem ID | 5290 | Appearance | Powder |
| Formula | C19H21NO4 | M.Wt | 327.37 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | DMSO | ||
| Chemical Name | 3,9-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,10-diol | ||
| SMILES | COC1=C(C=C2C3CC4=C(CN3CCC2=C1)C(=C(C=C4)O)OC)O | ||
| Standard InChIKey | JKPISQIIWUONPB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H21NO4/c1-23-18-8-12-5-6-20-10-14-11(3-4-16(21)19(14)24-2)7-15(20)13(12)9-17(18)22/h3-4,8-9,15,21-22H,5-7,10H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | L-Stepholidine, which has dual actions on dopamine D1 and D2 receptors, attenuates heroin self-administration and cue-induced reinstatement. It also elicits anti-dyskinesia effects. |
| Targets | Dopamine Receptor | 5-HT Receptor |
| In vivo | L-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats.[Pubmed: 24145772]Neuroreport. 2014 Jan 8;25(1):7-11.Opiate addiction is a chronic, relapsing brain disease characterized by persistent and uncontrolled drug-seeking behavior despite negative effects. L-Stepholidine (L-SPD) is an alkaloid extract of the Chinese herb Stephania intermedia with dopamine D1 receptor partial agonistic and D2 receptor antagonistic dual actions. The unique pharmacological profile of L-SPD suggests that L-SPD may be effective for the treatment of opiate addiction. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.[Pubmed: 18707801]Neurobiol Aging. 2010 Jun;31(6):926-36.L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) remains a challenge in Parkinson's disease (PD) drug therapy. |
| Kinase Assay | l-Stepholidine-induced excitation of dopamine neurons in rat ventral tegmental area is associated with its 5-HT(1A) receptor partial agonistic activity.[Pubmed: 20803620]Synapse. 2011 May;65(5):379-87.We studied the effects of L-Stepholidine on the activity of dopamine (DA) neurons in the ventral tegmental area (VTA) using in vivo single-unit recording technique in rats. |
| Animal Research | L-stepholidine, a natural dopamine receptor D1 agonist and D2 antagonist, inhibits heroin-induced reinstatement.[Pubmed: 24269875]Neurosci Lett. 2014 Jan 24;559:67-71.L-Stepholidine (l-SPD), an alkaloid extract of the Chinese herb Stephania intermedia, is the first compound known to exhibit mixed dopamine D1 receptor agonist/D2 antagonist properties and is a potential medication for the treatment of opiate addiction. The aim of the present study was to investigate the effects of pretreatment with L-SPD on heroin-seeking behavior induced by heroin priming. |
L-Stepholidine Dilution Calculator
L-Stepholidine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0546 mL | 15.2732 mL | 30.5465 mL | 61.093 mL | 76.3662 mL |
| 5 mM | 0.6109 mL | 3.0546 mL | 6.1093 mL | 12.2186 mL | 15.2732 mL |
| 10 mM | 0.3055 mL | 1.5273 mL | 3.0546 mL | 6.1093 mL | 7.6366 mL |
| 50 mM | 0.0611 mL | 0.3055 mL | 0.6109 mL | 1.2219 mL | 1.5273 mL |
| 100 mM | 0.0305 mL | 0.1527 mL | 0.3055 mL | 0.6109 mL | 0.7637 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
L-Stepholidine is a naturally occurring chemical compound found in the herb Stephania intermedia. L-Stepholidine is a dual D2 receptor antagonist and D1 receptor agonist. L-Stepholidine is used for preventing or treating neural diseases. The neural diseases comprise parkinsonism, schizophrenia and dyskinesia which is produced by L-DOPA or medicine to treat schizophrenia. L-Stepholidine has shown antipsychotic activity in animal studies.
- 12-O-tetradecanoylphorbol-13-acetate
Catalog No.:BCN2511
CAS No.:16561-29-8
- DEPBT
Catalog No.:BCC2811
CAS No.:165534-43-0
- Di-Dnp-L-Lysine
Catalog No.:BCC8939
CAS No.:1655-49-8
- 16-Hydroxy-2-oxocleroda-3,13-dien-15,16-olide
Catalog No.:BCN1536
CAS No.:165459-53-0
- bis[6-(5,6-dihydrochelerythrinyl)]amine
Catalog No.:BCN8232
CAS No.:165393-48-6
- SA 4503 dihydrochloride
Catalog No.:BCC6339
CAS No.:165377-44-6
- Hemiphroside B
Catalog No.:BCN1731
CAS No.:165338-28-3
- Hemiphroside A
Catalog No.:BCN1730
CAS No.:165338-27-2
- 1-Ethyl-3-nitrophthalate
Catalog No.:BCC8466
CAS No.:16533-45-2
- Cleroindicin E
Catalog No.:BCN1729
CAS No.:165197-71-7
- Shizukaol G
Catalog No.:BCN7879
CAS No.:165171-11-9
- Shizukaol E
Catalog No.:BCN7880
CAS No.:165171-09-5
- Methyl 6-acetoxyangolensate
Catalog No.:BCN1732
CAS No.:16566-88-4
- Torososide A
Catalog No.:BCN4694
CAS No.:165689-32-7
- Linezolid
Catalog No.:BCC2496
CAS No.:165800-03-3
- Eperezolid
Catalog No.:BCC5177
CAS No.:165800-04-4
- 1-Hydroxy-N-methylacridone
Catalog No.:BCN7551
CAS No.:16584-54-6
- Naltrexone
Catalog No.:BCC1783
CAS No.:16590-41-3
- Calystegine A5
Catalog No.:BCN1887
CAS No.:165905-26-0
- (-)-Tetramisole
Catalog No.:BCC4670
CAS No.:16595-80-5
- Z-Thr-OBzl
Catalog No.:BCC2737
CAS No.:16597-50-5
- Cyclogrifolin
Catalog No.:BCN7547
CAS No.:1660156-04-6
- 3,4-O-dimethylcedrusin
Catalog No.:BCN8211
CAS No.:166021-14-3
- Ginkgolic acid C15:0
Catalog No.:BCN2483
CAS No.:16611-84-0
l-Stepholidine-induced excitation of dopamine neurons in rat ventral tegmental area is associated with its 5-HT(1A) receptor partial agonistic activity.[Pubmed:20803620]
Synapse. 2011 May;65(5):379-87.
RATIONALE: L-Stepholidine (l-SPD), a tetrahydroprotoberberine alkaloid, possesses a pharmacological profile of a D(1)/5-HT(1A) agonist and a D(2) antagonist. This unique pharmacological profile makes it a promising novel antipsychotic candidate. Preliminary clinical trials and animal experiments suggest that l-SPD improves both positive and negative symptoms of schizophrenia without producing significant extrapyramidal side effects. To further explore the antipsychotic mechanisms of the drug, we studied the effects of l-SPD on the activity of dopamine (DA) neurons in the ventral tegmental area (VTA) using in vivo single-unit recording technique in rats. RESULT: We found that l-SPD increased VTA DA neurons firing rate and induced slow oscillation in firing pattern. Moreover, l-SPD, not clozapine, reversed d-amphetamine-induced inhibition which induced an excitation of VTA DA neurons. Furthermore, our data indicated that the excitatory effect of l-SPD is associated with its partial agonistic action for the 5-HT(1A) receptor since the 5-HT(1A) receptor antagonist WAY100635 could block the l-SPD-induced excitatory effect. However, activation of 5-HT(1A) receptor alone by specific agonist (+/-)-8-Hydroxy-2-(dipropylamino) tetralin (8-OH-DPAT) was insufficient to elicit excitation of VTA DA neurons, but the excitation of 8-OH-DPAT on VTA DA neurons was elicited in the presence of D(2)-like receptors antagonist raclopride. Collectively, these results indicate that l-SPD excited VTA DA neurons requiring its D(2)-like receptors antagonistic activity and 5-HT(1A) receptor agonistic activity. CONCLUSION: The present data demonstrate that D(2) receptor antagonist/5-HT(1A) receptor agonistic dual properties modulate dopaminergic transmission in a unique pattern that may underlie the different therapeutic responses between l-SPD and other atypical antipsychotic drugs.
L-stepholidine, a natural dopamine receptor D1 agonist and D2 antagonist, inhibits heroin-induced reinstatement.[Pubmed:24269875]
Neurosci Lett. 2014 Jan 24;559:67-71.
L-Stepholidine (l-SPD), an alkaloid extract of the Chinese herb Stephania intermedia, is the first compound known to exhibit mixed dopamine D1 receptor agonist/D2 antagonist properties and is a potential medication for the treatment of opiate addiction. The aim of the present study was to investigate the effects of pretreatment with L-SPD on heroin-seeking behavior induced by heroin priming. Male Sprague-Dawley rats were trained to self-administer heroin (0.05mg/kg per infusion) under a fixed ratio 1 schedule for 12 consecutive days and nose-poke responding was extinguished for 12 days, after which reinstatement of drug seeking was induced by heroin priming. Pretreatment with L-SPD (2.5, 5.0 and 10.0mg/kg, i.p.) inhibited the heroin-induced reinstatement of heroin-seeking behavior. Importantly, L-SPD did not affect locomotion, indicating that the observed effects of L-SPD on reinstatement are not the result of motor impairments. The present data suggested that l-SPD inhibits heroin-induced reinstatement and its potential for the treatment of heroin relapse.
L-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats.[Pubmed:24145772]
Neuroreport. 2014 Jan 8;25(1):7-11.
Opiate addiction is a chronic, relapsing brain disease characterized by persistent and uncontrolled drug-seeking behavior despite negative effects. L-Stepholidine (L-SPD) is an alkaloid extract of the Chinese herb Stephania intermedia with dopamine D1 receptor partial agonistic and D2 receptor antagonistic dual actions. The unique pharmacological profile of L-SPD suggests that L-SPD may be effective for the treatment of opiate addiction. The aim of this study was to characterize the effects of L-SPD on heroin self-administration on a fixed-ratio 1 schedule and cue-induced reinstatement under an extinction/reinstatement protocol. The effect of L-SPD on the locomotor activity of heroin-free rats was also tested. We found that 2.5, 5, and 10 mg/kg of L-SPD attenuated heroin self-administration and cue-induced reinstatement without affecting locomotor activity. These results showed that L-SPD, which has dual actions on dopamine D1 and D2 receptors, attenuates heroin self-administration and cue-induced reinstatement.
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.[Pubmed:18707801]
Neurobiol Aging. 2010 Jun;31(6):926-36.
L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) remains a challenge in Parkinson's disease (PD) drug therapy. In the present study, we examined the effect of L-Stepholidine (L-SPD), a known dual dopamine receptor agent, on LID in 6-hydroxydopamine (6-OHDA)-lesioned PD rat model. Daily administration of L-DOPA to PD rats for 22 days induced steady expression of LID, co-administration of L-SPD with L-DOPA significantly ameliorated LID without compromising the therapeutic potency of L-DOPA, indicating that L-SPD attenuated LID development. L-SPD alone elicited stable contralateral rotational behavior without inducing significant dyskinesia. Acute administration of L-SPD to rats with established LID produced significant relief of dyskinesia; this effect was mimicked by D(2) receptor antagonist haloperidol, but blunted by 5-HT(1A) receptor antagonist WAY100635. Furthermore, the mRNA level of 5-HT(1A) decreased significantly on 6-OHDA-lesioned striata, whereas chronic L-SPD treatment restored 5-HT(1A) receptor mRNA level on the lesioned striata. The present data demonstrated that L-SPD elicited antidyskinesia effects via both dopamine (D(2) receptor antagonistic activity) and nondopamine (5-HT(1A) agonistic activity) mechanisms.
